Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Leo Pharma partners with PellePharm in rare skin diseases; gains option to acquire

Executive Summary

Leo Pharma AS and PellePharm Inc. have agreed to collaborate on the development and commercialization of therapeutics for rare skin diseases, including Gorlin syndrome, a rare genetic form of basal cell carcinoma (BCC). Leo has an option to acquire PellePharm outright.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes M&A Option
    • Includes Equity
    • R+D and Marketing-Licensing
    • Includes Royalty or Profit Split Information

Related Companies

Advertisement
UsernamePublicRestriction

Register